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Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein
that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and
therapeutic consequences of this missplicing are not well understood. Here we have
provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome,
proteome, and metabolome of human cells, leading to missplicing-associated
downregulation of metabolic genes, decreased mitochondrial respiration, and suppression
of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to
deprivation of the nonessential amino acid serine, which was mediated by missplicing-
associated downregulation of the serine synthesis pathway enzyme PHGDH. This
vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and
glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings
describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new
therapeutic strategy against SF3B1MUT cancers.
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Introduction
Since their identification in 2011, mutations in spliceosome genes 
have been found in numerous human malignancies (1). Among 
the most broadly implicated genes is SF3B1, recurrently mutated 
in myelodysplastic syndrome (MDS), chronic lymphocytic leu-
kemia, uveal melanoma, breast carcinoma, pancreas adenocar-
cinoma, lung adenocarcinoma, prostate adenocarcinoma, and 
many other cancers (2–8). Part of the U2snRNP complex, SF3B1 
normally serves in the proper selection of 3′ acceptor sequences in 
pre-mRNA splicing reactions. In cancer, SF3B1 mutations create 
a neomorphic spliceosome protein that induces cryptic 3′ splice 
site selection by favoring an alternative branch point sequence (9, 
10). The resulting aberrant splice junctions frequently lead to non-
sense-mediated decay (NMD) and downregulation of mRNA from 
hundreds of affected genes (9). Yet, less is known about how these 
splicing alterations affect the downstream cellular processes and 
oncogenic properties of SF3B1MUT cells.
Despite this still nascent understanding of its biology, mutant 
SF3B1 has already become a target for novel therapeutic strategies, 
as many SF3B1MUT cancers have few effective treatments (11). How-
ever, unlike canonical oncogene targets like BCR-ABL, SF3B1 muta-
tions do not seem to create “oncogene addiction,” as cancer cells 
with native SF3B1 mutation do not require the continued presence 
of mutant protein for their in vitro viability (11, 12). Therefore, rather 
than directly inhibiting the mutant protein, successful therapeutic 
strategies may come from a synthetic lethal approach, whereby the 
treatment targets a process whose disruption would be tolerated 
by normal cells, but detrimental to those with an SF3B1 mutation. 
Among the most attractive processes to target in this way are those 
that are nonessential to normal cells, as this will minimize toxicity 
of the treatment and facilitate its combination with other therapies. 
To date, processes whose disruption is deleterious to SF3B1MUT cells 
but nonessential to normal cells have not been identified.
Here we report investigations into the downstream function-
al consequences of SF3B1 mutations in human cells, providing 
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misspliced genes were affected by at least one aberrant junction 
predicted to be NMD-sensitive, compared with none of those 
upregulated and misspliced (Figure 1D and Supplemental Tables 
1 and 3). Thus, mutant SF3B1 induces aberrant splicing dominated 
by cryptic 3′ site selection and NMD-associated mRNA downreg-
ulation in untransformed breast epithelial cells, extending obser-
vations from transformed cell lines (9–11).
To evaluate the disease relevance of these findings, we com-
pared the junction usage profile in our MCF-10A model with 
that of SF3B1MUT human breast tumors from TCGA, utilizing the 
analysis of Darman et al. (9). Of the 262 junctions upregulated in 
SF3B1MUT breast tumors in their study, 43% (113/262) were among 
the 685 junctions increased in our SF3B1K700E knockins, a highly 
significant overlap (Figure 1E and Supplemental Table 1). We then 
compared the whole-gene mRNA expression of our model with 
that of 2 independent transcriptome data sets of human breast 
tumors: TCGA and METABRIC (16, 17). Of the genes downregu-
lated in SF3B1MUT MCF-10A cells, 32%, 21%, and 17% were also 
downregulated in SF3B1MUT tumors from METABRIC, TCGA, or 
both data sets (Figure 1E and Supplemental Table 4), respectively. 
Notably, 66% (25/38) of genes downregulated and misspliced in 
MCF-10A cells were also among those downregulated in one or 
more of the SF3B1MUT breast tumor data sets (Figure 1E and Sup-
plemental Table 4), demonstrating the contextual robustness of 
missplicing-associated downregulation of mRNA. In contrast, 
overlap was lower between upregulated genes in SF3B1MUT MCF-
10A cells and breast tumors (Figure 1E and Supplemental Table 
5). Taken together, these findings validate the disease relevance 
of our isogenic cell model and provide experimental evidence for 
determining which transcriptome alterations are directly caused 
by mutant SF3B1 in human breast tumors.
Mutant SF3B1 reshapes the proteome of breast epithelial cells. 
Although transcriptional effects of SF3B1 mutation have now 
been observed in several contexts, less is known about how these 
alterations affect the proteome. We therefore performed pep-
tide mass spectrometry on isogenic MCF-10A cells using stable 
isotope labeling of amino acids in culture (SILAC). This exper-
iment generated abundance values for 5,715 proteins. Using a 
log2 abundance ratio cutoff of ±0.5, we identified nearly twice as 
many proteins downregulated by SF3B1K700E than upregulated: 
381 versus 204 (Supplemental Tables 6 and 7). Integrating these 
results with our transcriptome analysis revealed that downreg-
ulated proteins exhibited missplicing of corresponding mRNA 
more frequently than upregulated ones: 13% (51/396) versus 3.0% 
(6/203), respectively (χ2 P < 0.01) (Figure 2A and Supplemental 
Table 1 and Supplemental Table 6). This analysis further revealed 
a group of downregulated proteins with concomitant decrease in 
whole-gene mRNA (Figure 2B, red box) and another whose whole-
gene mRNA was not significantly changed (Figure 2B, blue box). 
This suggests mutant SF3B1 may downregulate some proteins by 
direct suppression of mRNA (i.e., through missplicing-induced 
NMD) and others through translational or posttranslational mech-
anisms. Indeed, among downregulated and misspliced proteins, 
27% (14/51) showed evidence of likely suppression by NMD, 
with reduction in whole-gene mRNA expression and aberrant 
junctions predicted to be NMD-sensitive (Figure 2, A and B, and 
Supplemental Table 6), and another 49% (25/51) had unchanged 
evidence that mutant SF3B1 induces a specific remodeling of the 
proteome, cryptic splicing-induced downregulation of metabolic 
genes, and reprogramming of cellular metabolism. We also find 
that SF3B1 mutations create a heightened sensitivity to depriva-
tion of the nonessential amino acid serine, suggesting a novel 
therapeutic strategy for targeting SF3B1MUT cancers.
Results
Knockin of mutant SF3B1 alters the transcriptome of breast epitheli-
al cells. SF3B1 is recurrently mutated in 2% of breast cancers and 
associates with poor prognosis in subgroups of patients, but the 
functional role of the mutation in this cellular context has been 
unexplored (13, 14). We therefore first aimed to characterize the 
isolated consequences of SF3B1 mutations in untransformed 
human breast epithelial cells. We used AAV-mediated gene tar-
geting to engineer heterozygous knockins of the dominant K700E 
hotspot in spontaneously immortalized but nontumorigenic 
MCF-10A breast epithelial cells. To control for nonspecific effects 
of gene targeting, we also generated knockins of a synonymous 
base substitution at R702 that is a single nucleotide polymorphism 
(SNP) in the human population (15), and targeted WT (TWT) 
clones, where cells experience gene targeting, but remain WT 
(Supplemental Figure 1A; supplemental material available online 
with this article; https://doi.org/10.1172/JCI125022DS1). Four 
mutant and 4 control clones were independently isolated, and het-
erozygosity of the knockins was confirmed at both the DNA and 
mRNA levels (Supplemental Figure 1B).
Splice junction analysis of whole transcriptome RNA-seq from 
2 mutant and 2 control clones revealed SF3B1K700E-dependent 
alternative splicing. At a P value less than 0.01 and FDR less than 
0.05, we identified 685 junctions whose usage was upregulated in 
SF3B1K700E cells (Supplemental Table 1). Alternative 3′ splice site 
selection (A3SS) was the most frequent splicing event (49% of all 
junctions) (Figure 1A), with enrichment of cryptic acceptors 10–30 
nucleotides upstream of canonical ones (Figure 1B). More than 
half (56%) of the SF3B1K700E-enriched junctions were not anno-
tated in transcriptome databases of normal human tissue (Fig-
ure 1A), compared with 12% of junctions overall, demonstrating 
enrichment of novel junctions in SF3B1K700E cells. To orthogonally 
validate these RNA-seq data in all mutant and control MCF-10A 
clones, PCR was performed on candidate aberrant junctions in the 
metabolic genes MUT (methylmalonyl-CoA mutase) and DLST 
(dihydrolipoamide S-succinyltransferase) (Figure 1C). To contex-
tualize these findings in another genetic background, we also cre-
ated an SF3B1K700E knockin clone from human mammary epithelial 
cells immortalized by telomerase (hTERT-IMECs) (Supplemental 
Figure 1C). These cells exhibited the same cryptic splicing events 
seen in our MCF-10A knockins (Supplemental Figure 2A). We 
then determined how whole-gene mRNA expression is affected by 
this aberrant splicing. At a log2FC of ±0.5 and FDR less than 0.01, 
we identified 301 downregulated and 231 upregulated genes in 
SF3B1MUT cells (Supplemental Tables 2 and 3). Downregulat-
ed genes were more frequently subject to aberrant splicing than 
upregulated ones: 13% (38/301) versus 2.6% (6/231), respectively 
(χ2 P < 0.0001) (Figure 1D and Supplemental Tables 1 and 2). Mech-
anistically, this association was likely driven by nonsense-medi-
ated mRNA decay (NMD), as 76% (29/38) of downregulated and 
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Figure 1. Mutant SF3B1 alters the transcriptome 
of breast epithelial cells. (A) Classification of 
splice junctions upregulated in SF3B1K700E MCF-
10A cells. A3SS, alternate 3′ splice site; A5SS, 
alternate 5′ splice site; EXI, exon inclusion; EXE, 
exon exclusion. Known refers to junctions anno-
tated, and novel refers to those not annotated, 
in transcriptional databases of normal human 
tissue. (B) Nucleotide position of cryptic 3′ splice 
sites, relative to canonical AG, for all aberrant 
junctions in SF3B1K700E MCF-10A cells. (C) PCR 
validation of missplicing of the MUT and DLST 
genes in all 4 SF3B1MUT MCF-10A clones. Data are 
representative of 2 independent experiments. (D) 
Number of aberrant junctions per gene plotted 
against whole-gene mRNA expression in isogen-
ic MCF-10A cells. Green, at least one NMD-sen-
sitive junction; blue, NMD-insensitive junctions. 
(E) Transcriptional overlap between SF3B1MUT 
human breast tumors in TCGA and METABRIC 
data sets and SF3B1K700E MCF-10A cells. Overlap 
of aberrant junctions (upper) and whole-gene 
mRNA expression (lower) are shown. The smaller 
circles contain those genes with both altered 
whole-gene expression and aberrant junctions in 
SF3B1K700E MCF-10A cells.
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Figure 2. Mutant SF3B1 reshapes the 
proteome of breast epithelial cells. (A) 
Aberrant junctions per gene plotted against 
protein expression determined by SILAC in 
isogenic MCF-10A cells. Green indicates genes 
with downregulated whole-gene mRNA and 
NMD-sensitive junctions. (B) Integration of 
protein and whole-gene mRNA expression in 
isogenic MCF-10A cells. Misspliced genes are 
in orange. The red box shows a population 
of genes with downregulated mRNA and 
protein, and the blue box shows a popula-
tion with downregulated protein, but not 
mRNA. (C) Western blot validation of protein 
downregulation for misspliced genes MUT 
and DLST in isogenic MCF-10A cells. Data are 
representative of 2 independent experiments. 
(D) Quantification of cryptic SLC3A2 peptide 
abundance by integration of ion counts 
from mass spectra in isogenic MCF-10A cells 
obtained by SILAC. (E) RNA-seq correlation of 
cryptic splicing of SLC3A2 in isogenic MCF-10A 
cells, showing insertion of A-P-I-S between 
exons 5 and 6. PSI of the cryptic junction is 
shown. (F) GO pathway enrichment analysis of 
proteins differentially expressed in SF3B1K700E 
MCF-10A cells.
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complex III (Figure 3A) (20, 21). Among the 50 most downregulat-
ed proteins in our SILAC experiment, 7 were part of this complex 
(Figure 3A). None of these 7 had SF3B1MUT-dependent changes in 
whole-gene mRNA expression (Supplemental Table 2), suggesting 
their downregulation was at the protein level and not a direct result 
of missplicing. However, the assembly factor UQCC1 was heavily 
misspliced, with multiple aberrant transcripts containing cryp-
tic terminal exons (Figure 3B). Though truncated, these aberrant 
transcripts would be NMD-insensitive, and their presence likely 
explains why the whole-gene mRNA expression (i.e., the sum of 
all isoforms) of UQCC1 was not lower by RNA-seq. Yet full-length, 
canonical UQCC1 transcript was indeed lower in SF3B1K700E cells 
(Figure 3B), consistent with a zero-sum competition model of 
splicing between U2 snRNP complexes with WT or mutant SF3B1 
(9). UQCC1 was not a protein captured by SILAC, but Western blot-
ting revealed it to be decreased in SF3B1K700E cells, along with other 
complex III proteins (Figure 3C). We then constitutively expressed 
canonical UQCC1, and this rescued not only UQCC1 levels but also 
levels of other complex III proteins in SF3B1K700E MCF-10A cells 
(Figure 3C). UQCC1 and UQCC2 were also decreased by SF3B1K700E 
in hTERT-IMEC cells, although the downregulation of mature 
complex III proteins was less pronounced, perhaps due to a great-
er baseline reserve of the UQCC1 assembly factor in this cell line 
(Supplemental Figure 3). SF3B1MUT breast cancers from TCGA also 
did not show reduced whole-gene UQCC1 expression by RNA-seq, 
but they did by microarray analysis, whose probes capture canon-
ical, but not cryptic, mRNA (Supplemental Figure 4). UQCC1 was 
also the single most downregulated gene in SF3B1MUT tumors in the 
METABRIC data set, which used a microarray platform for mRNA 
analysis (Supplemental Figure 4). These data show that physiolog-
ic expression of mutant SF3B1 is sufficient to downregulate mito-
chondrial complex III levels, likely through missplicing of UQCC1.
In transferring electrons from ubiquinol to cytochrome c, com-
plex III fuels oxidative phosphorylation as well as the regeneration 
of electron acceptors for aspartate biosynthesis (22, 23). We there-
fore sought to determine whether the observed SF3B1MUT-induced 
protein changes are accompanied by metabolic alterations. We first 
performed targeted metabolomics using liquid chromatography 
electrospray ionization tandem mass spectrometry (LC-ESI-MS/
MS) in our isogenic cells, quantifying energy-relevant amino acids 
and metabolites involved in glycolysis and the TCA cycle. We val-
idated the metabolomics platform using cells exposed to the bigu-
anide metformin, which induced several known metabolic conse-
quences of this drug in control MCF-10A cells, including increased 
lactate, α-ketoglutarate, and serine, along with decreased citrate, 
succinate, and aspartate (24). Interestingly, mutant SF3B1 did 
induce multiple alterations in energy metabolites, including 
decreases in the TCA cycle metabolites succinate, fumarate, and 
malate; increases in glucose and 3-hydroxybutyrate; and decreases 
in amino acids such as serine, glycine, and aspartate (Figure 3D). 
For orthogonal validation, we confirmed decreased aspartate in an 
independent SF3B1K700E MCF-10A clone using a fluorometric assay 
(Supplemental Figure 5). While attributions of metabolite abun-
dance to particular protein expression levels are made difficult by 
the complex interplay of metabolite and enzyme dynamics (25), 
the finding of decreased aspartate in SF3B1MUT cells may nonethe-
less be suggestive of ETC impairment, as aspartate biosynthesis is 
whole-gene mRNA expression and aberrant junctions predicted to 
be NMD-insensitive (Figure 2, A and B, and Supplemental Table 
6). For the few proteins upregulated and misspliced, whole-gene 
mRNA was not increased, suggesting translational or posttransla-
tional mechanisms may be at work (Figure 2, A and B, and Supple-
mental Table 7). Importantly, we orthogonally validated candidate 
protein alterations with Western blotting in both our MCF-10A 
and hTERT-IMEC isogenic models (Figure 2C and Supplemental 
Figure 2B). These data indicate that the predominant association 
of missplicing by SF3B1MUT with down, rather than up, regulation 
of misspliced genes observed at the transcript level also extends to 
the proteome in breast epithelial cells.
Because SILAC quantifies the most abundant fraction of the 
proteome—and because the splicing pattern of most genes is a 
single dominant isoform and several less abundant minor ones—
the above analysis in fact reflects how mutant SF3B1 affects the 
expression of dominant protein isoforms (18, 19). We therefore 
next sought to determine whether any known or novel alterna-
tive splice junctions upregulated by mutant SF3B1 produce cor-
responding junction-spanning peptides. Known alternative splice 
isoforms of any kind could only be delineated in 2.5% (141/5,715) 
of our identified proteins, and this set of isoforms did not hap-
pen to contain any of the known junctions upregulated by mutant 
SF3B1. We did, however, find one peptide that spanned a novel 
cryptic 3′ splice acceptor site in the heavy chain of the integrin 
protein CD98, also known as SLC3A2. In each SF3B1K700E clone, 
abundance values of this cryptic peptide were 16-fold higher than 
the low-level expression in control cells (Figure 2D). The protein 
change was an insertion of 4 amino acids (A-P-I-S), and RNA-seq 
data showed the corresponding cryptic transcript resulting from 
insertion of the 12-bp intronic sequence preceding exon 5 that 
encodes these residues (Figure 2E). Mirroring the peptide-level 
quantification, the percent spliced in (PSI) of this cryptic splice 
junction was 34-fold higher (11 vs. 0.3%, P value = 5.89 × 10–9) in 
SF3B1K700E cells (Figure 2E). Thus, cryptic protein can be produced 
in breast epithelial cells following physiologic, heterozygous 
expression of mutant SF3B1.
Lastly, we subjected all protein expression changes, whether 
associated with direct missplicing or not, to Gene Ontology anal-
ysis. Among proteins downregulated in SF3B1K700E cells, there was 
a notable enrichment of pathways involved in energy metabolism, 
while upregulated proteins showed enrichment of pathways involv-
ing mRNA processing, mRNA splicing, and chromosomal localiza-
tion of proteins (Figure 2F). Together, these data show that mutant 
SF3B1 reshapes the proteome in breast epithelial cells, producing 
missplicing-associated gene downregulation, cryptic protein, and 
altered expression of proteins in multiple cellular pathways.
Evidence for reprogramming of mitochondrial metabolism by 
SF3B1MUT in breast epithelial cells. Given the contextual robustness 
of missplicing-associated gene downregulation induced by mutant 
SF3B1, we next examined the metabolic pathways enriched in pro-
teins downregulated in SF3B1MUT cells. One notably specific signal 
was in the ubiquinol-cytochrome c oxidoreductase complex, also 
known as mitochondrial complex III of the electron transport chain 
(ETC). It is formed by assembly factors UQCC1 and UQCC2, which 
stabilize mitochondrial cytochrome B (MT-CYB) and deliver it to 
other ubiquinol-cytochrome c reductase proteins to form mature 
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an essential function of mitochondrial respiration in multiple cell 
contexts (22, 23, 26–28). To test mitochondrial respiration directly, 
we measured oxygen consumption rate in 2 mutant and 2 WT MCF-
10A clones with a Seahorse XF Analyzer, and this demonstrated 
that both basal and maximal cellular respiration were decreased by 
SF3B1MUT (Figure 3E and Supplemental Figure 6). In contrast, extra-
cellular acidification rate was unaffected (Supplemental Figure 6). 
Together, these results provide evidence that SF3B1MUT induces a 
reprogramming of mitochondrial metabolism characterized by a 
decreased capacity for cellular respiration in breast epithelial cells.
Figure 3. Evidence for reprogramming of mitochondrial metabolism in SF3B1MUT cells. (A) Complex III assembly. Blue proteins were captured by SILAC 
in isogenic MCF-10A cells, with SF3B1MUT/SF3B1WT abundance ratios labeling them. (B) RNA-seq from isogenic MCF-10A cells shows UQCC1 is misspliced 
by SF3B1MUT (upper), creating transcripts with cryptic terminal exons (lower left). Canonical, but not whole-gene, UQCC1 mRNA is reduced in RNA-seq 
data (lower right). ****P < 0.0001 for t test comparing canonical FPKM in all mutant to all WT. (C) Western blotting shows downregulated complex III in 
isogenic MCF-10A cells (left), and canonical UQCC1 overexpression rescues complex III levels in SF3B1MUT cells (right). Vec, vector. Data are representative of 
2 independent experiments. Upper left panel represents the same membrane previously blotted for MUT and DLST in Figure 2C. (D) Metabolite quantifica-
tion in isogenic MCF-10A cells. Three biological replicates were used in R702R1 and K700E2 cells, 2 replicates for R702R1 + metformin (Met), and Z scores 
are shown. (E) Oxygen consumption rate (OCR) in isogenic MCF-10A cells as measured by a Seahorse XF Analyzer. Data are representative of 2 independent 
experiments, and 6 biologic replicates per conditions were used.
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Figure 4. Mutant SF3B1 suppresses the serine synthesis path-
way in breast epithelial cells. (A) Serine synthesis pathway. 
3PG, 3-phosphoglycerate; PHP, phosphohydroxypyruvate; pSer, 
phosphoserine. (B) RNA-seq of isogenic MCF-10A cells showing 
cryptic splicing of PHGDH leading to NMD. (C) Validation of 
cryptic splicing (upper) of PHGDH in MCF-10A and hTERT-IMEC 
isogenic cells, as well as downregulation of PHGDH protein 
(lower). Data are representative of 2 independent experiments. 
(D) Quantification (left) and representative images (right) of 
growth of isogenic MCF-10A cells with and without serine and 
glycine (SG). Scale bars: 100 μm. (E) Quantification of short-term 
(top) and representative images of long-term (bottom) growth 
of isogenic hTERT-IMEC cells with or without SG. For both breast 
epithelial cell models, data are representative of 2 independent 
experiments, and 3 biologic replicates were used per condition. 
****P < 0.0001 for t test comparing all mutant to all WT, but 
independent clones are also shown. (F) Serine synthesized from 
13C-glucose (M+3) is reduced in SF3B1K700E hTERT-IMEC cells at 
baseline and upon SG starvation. Three biologic replicates per 
condition from one experiment are shown. **P < 0.01 for t test 
comparing the M+3 fraction between WT and mutant cells in 
each media condition.
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compared with SF3B1WT cells, with a fold change of 0.581 (Supple-
mental Figure 8 and Supplemental Table 9), similar to SF3B1MUT 
MCF-10A cells with a fold change of 0.497 (Supplemental Table 
8). In media containing SG (+SG media), the percentage of M+3 
serine synthesized from 13C-glucose in SF3B1WT hTERT-IMEC 
cells was 2.7% of the total serine, comparable to baseline serine 
synthesis rates in regular media of breast epithelial cells seen in 
other studies (Figure 4F, Supplemental Figure 8, and Supplemen-
tal Table 9) (36, 37). In contrast, the percentage of M+3 serine in 
SF3B1K700E hTERT-IMECs was 0.19% of the total serine in +SG 
media, equal to only 4% of the M+3 serine in SF3B1WT cells (Fig-
ure 4F, Supplemental Figure 8, and Supplemental Table 9). Upon 
starvation of serine and glycine, both the absolute total serine and 
absolute M+3 serine were decreased compared with +SG condi-
tions in SF3B1WT cells, but the percentage of total serine made up 
by M+3 serine increased to 77%, consistent with previous work on 
serine isotope changes upon SG starvation (Figure 4F, Supplemen-
tal Figure 8, and Supplemental Table 9) (38, 39). In contrast, the 
absolute total serine decreased even further in SF3B1K700E cells in 
–SG media, to 20% that of SF3B1WT cells, and the M+3 serine frac-
tion comprised only 2.6% of the total, representing 0.7% of the 
M+3 serine in SF3B1WT cells in –SG conditions (Figure 4F, Supple-
mental Figure 8, and Supplemental Table 9). These data indicate 
that de novo serine synthesis is severely impaired in SF3B1K700E 
breast epithelial cells, and the inability of these cells to adequately 
generate flux through the serine synthesis pathway likely contrib-
utes to their growth impairment in –SG conditions.
Transformed SF3B1MUT cells exhibit PHGDH downregulation and 
vulnerability to serine starvation. Deprivation of serine and glycine 
has now been shown to suppress growth of certain cancers in vitro 
and in vivo, introducing a novel anticancer treatment strategy (24, 
26–28). We therefore asked whether SF3B1MUT induces PHGDH 
downregulation and vulnerability to serine starvation in fully trans-
formed human cancer cells. In breast cancer, SF3B1 mutations occur 
predominantly in hormone receptor–positive tumors, so we utilized 
an SF3B1K700E knockin of ER-positive T47D breast cancer cells. As 
in untransformed breast epithelial cells, PHGDH mRNA was mis-
spliced and its protein was downregulated by SF3B1K700E in T47D 
cells (Figure 5A). We then assayed the 3D growth of these isogenic 
cells in conditions with and without SG. Notably, SF3B1K700E T47D 
cells showed no significant growth deficit in regular media com-
pared with SF3B1WT cells (Figure 5A), in contrast to the baseline 
slower growth exhibited by untransformed SF3B1MUT breast epithe-
lial cells (Supplemental Figure 7). Additionally, the growth of WT 
T47D cells was not significantly impaired by SG starvation in these 
conditions, indicating adequate de novo serine synthesis capacity 
in these cells (Figure 5A). In contrast, the size of SF3B1K700E T47D 
spheroids was reduced by 30%–40% in –SG media in 2 indepen-
dent knockin clones, as compared with those grown in +SG, demon-
strating that SF3B1MUT induces vulnerability to serine and glycine 
starvation in fully transformed breast cancer cells (Figure 5A).
Given that mutation-targeting cancer treatments are begin-
ning to transcend the traditional boundaries of tissue of origin 
in their applications (40), we next sought to determine whether 
SF3B1MUT cancer cells from other tissue types might exhibit this 
vulnerability. SF3B1 mutations are more common in hematolog-
ic malignancies than in solid tumors, and we found that PHGDH 
Mutant SF3B1 suppresses the serine synthesis pathway in breast 
epithelial cells. Another metabolic gene whose expression was 
strikingly affected by SF3B1MUT was phosphoglycerate dehydro-
genase (PHGDH), an enzyme that catalyzes the conversion of 
3-phosphoglycerate to phosphohydroxypyruvate as the rate-limit-
ing step in de novo synthesis of the nonessential amino acid ser-
ine (Figure 4A). SF3B1MUT knockin breast epithelial cells exhibited 
enrichment of 2 different aberrant splice junctions in PHGDH, 
which are predicted to decrease total PHGDH mRNA expression 
by creating a cryptic terminal exon and inducing NMD, respec-
tively (Figure 4, B and C). Indeed, whole-gene mRNA expression 
was lower by RNA-seq in SF3B1MUT MCF-10A (Supplemental Table 
2), PHGDH protein was among the most downregulated proteins 
captured by SILAC (Supplemental Table 6), and Western blotting 
confirmed decreased PHGDH protein in both SF3B1MUT MCF-10A 
and hTERT-IMEC cells (Figure 4C). Moreover, in the TCGA and 
METABRIC data sets, PHGDH was among the most downregulat-
ed genes (Supplemental Table 4) in SF3B1MUT tumors.
Previous studies have shown that deliberate suppression of 
PHGDH or other components of the serine synthesis pathway ren-
ders mammalian cells less capable of growth and survival without 
exogenous serine, or, as is usually done in such studies, serine 
and glycine (SG), since serine can be synthesized directly from 
glycine (29–31). We therefore asked whether SF3B1MUT cells, with 
suppressed PHGDH levels, might exhibit a dependence on exog-
enous SG. When cultured in media without SG (–SG media), WT 
MCF-10A cells grew more slowly than in complete media, but cells 
nonetheless remained viable and mitotic (Figure 4D). In contrast, 
SF3B1K700E cells showed minimal growth without exogenous serine 
and glycine (Figure 4D). For hTERT-IMECs, WT cells were natu-
rally more capable of growing without SG than WT MCF-10As, yet 
SF3B1K700E hTERT-IMECs still showed minimal growth without 
SG in both short-term proliferation and long-term colony forma-
tion assays (Figure 4E). Of note, the baseline growth in full media 
of SF3B1K700E breast epithelial cell knockins was slower than that of 
control cells (Supplemental Figure 7), but SG starvation dispropor-
tionately suppressed growth from this lower baseline in SF3B1K700E 
cells (Figure 4, D and E). These data demonstrate that SF3B1MUT 
increases dependence on exogenous serine and glycine for growth 
in breast epithelial cells.
PHGDH downregulation and serine/glycine auxotrophy sug-
gest that serine synthesis could be impaired by SF3B1MUT. Indeed, 
our metabolomic analysis of isogenic MCF-10A cells did show 
decreased total intracellular serine and glycine levels in SF3B1K700E 
cells (Figure 3D). However, while suppression of the serine syn-
thesis pathway decreases total intracellular serine and glycine in 
certain cell types grown in regular media, in most cell types sup-
pression of the serine synthesis pathway will not decrease total 
intracellular serine and glycine unless the exogenous supply of ser-
ine is restricted (30, 32, 33). In contrast, the fraction of serine syn-
thesized de novo in cells, as revealed by isotope tracing of 13C-glu-
cose into M+3 serine, is ubiquitously decreased by suppression of 
the serine synthesis pathway in different cell types (33–35). There-
fore, to directly determine whether serine synthesis is decreased 
by SF3B1MUT, we performed isotope tracing of 13C-glucose in our 
isogenic hTERT-IMEC cells in both +SG and –SG conditions. The 
total serine was lower in SF3B1K700E hTERT-IMEC cells at baseline 
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In contrast, SF3B1K700E HNT34 cells and SF3B1K666N MUTZ3 cells 
were nonviable after 4 days without SG, and both cell lines showed 
aberrant splicing and decreased protein levels of PHGDH (Figure 
5C). We also confirmed deprivation of serine is principally respon-
sible for the suppressive effects of SG starvation in these cells 
(Supplemental Figure 10). Interestingly, a few SF3B1-WT leuke-
mia cell lines also had lower PHGDH expression (MV411, Mono-
mac-6, KG-1), and these cells did show greater growth suppression 
without SG than the other SF3B1-WT cell lines (Figure 5C). This 
suggests that downregulation of PHGDH by mechanisms other 
than missplicing by mutant SF3B1 may also predict for reliance on 
extracellular serine. Taken together, these data show that in both 
expression was downregulated in SF3B1MUT cases of myelodys-
plastic syndrome and acute myeloid leukemia in published gene 
expression data sets of these diseases (Supplemental Figure 9) (41, 
42). We then interrogated the effect of SG starvation on Nalm6 
leukemia cells with knockin of the SF3B1H662Q hotspot mutation 
(9). Compared with WT Nalm6 cells, SF3B1H662Q cells exhibited 
aberrant splicing of PHGDH, lower expression of PHGDH pro-
tein, and a heightened sensitivity to SG starvation (Figure 5B). 
We then turned to a panel of leukemia cell lines with or without 
native SF3B1 mutations. In 8 leukemia lines WT for SF3B1, all 
demonstrated growth and viability over 4 days without SG, though 
with variable amounts of partial growth suppression (Figure 5C). 
Figure 5. SF3B1MUT cancer cells show 
missplicing-associated downregula-
tion of PHGDH and vulnerability to 
SG starvation. (A) T47D breast cancer 
cells with knockin of SF3B1K700E show 
aberrant PHGDH splicing (upper left), 
decreased PHGDH protein (lower left), 
and decreased 3D colony growth in 
Matrigel (middle and right). Scale bars 
are 1 mm. Colony counts are from 6 bio-
logic replicates per cell line and data are 
from 2 independent experiments. **P < 
0.01 for t test comparing all mutant to 
all WT, but independent clones are also 
shown. (B) SF3B1H662Q Nalm6 knockins 
show aberrant PHGDH splicing (left), 
decreased PHGDH protein (middle), and 
lower relative growth in –SG (right). Cell 
counts are from 3 biologic replicates per 
condition, and data are representative 
of 3 independent experiments. ****P < 
0.0001 for t test compared with –SG for 
WT. (C) Leukemia cell lines with native 
SF3B1 mutation show PHGDH missplic-
ing, low PHGDH protein, and increased 
sensitivity to SG starvation. Absorbance 
of alamarBlue reaction product was 
quantified in –SG relative to +SG control 
after 8 and 24 hours of incubation in the 
viability reagent. Six biologic replicates 
were used for alamarBlue, and data are 
representative of 2 independent experi-
ments. ***P < 0.001; ****P < 0.0001 for 
t test comparing –SG with +SG.
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SF3B1K700E MCF-10A cells (Figure 6A). A similar rescue of growth 
without SG by PHGDH was also seen in both SF3B1K700E hTERT-
IMEC cells and SF3B1H662Q Nalm6 cells (Figure 6, B and C). These 
data support the idea that impaired serine synthesis due to mis-
splicing-associated downregulation of PHGDH contributes to the 
vulnerability to SG starvation of SF3B1MUT cells. Consistent with 
this, we also found that growth of SG-starved SF3B1MUT cells could 
be rescued by supplementation with phosphohydroxypyruvate 
(PHP), the reaction product of PHGDH that serves as the substrate 
for subsequent steps of the serine synthesis pathway (Figure 6D).
Dietary restriction of serine and glycine limit in vivo growth 
of SF3B1MUT tumors. Finally, we sought to determine whether 
knockin and naturally mutated cancer cells of multiple cell lineag-
es, SF3B1 mutation is associated with downregulation of PHGDH 
and heightened sensitivity to SG starvation.
PHGDH overexpression and PHP supplementation rescue growth 
without exogenous serine. To determine whether PHGDH downreg-
ulation is a mediator of this vulnerability, we reexpressed canon-
ical PHGDH in SF3B1K700E breast epithelial cells and SF3B1H662Q 
Nalm6 cells, creating 2 independently derived populations of 
PHGDH-overexpressing cells for each cell model, along with 2 
independently derived populations of GFP- or vector-overex-
pressing controls (Figure 6 and Supplemental Figure 11). In con-
trast to GFP, PHGDH was able to rescue cell growth without SG in 
Figure 6. PHGDH overexpression 
and PHP rescue growth without SG 
in SF3B1MUT cells. (A) Western blot of 
PHGDH levels in independent polyclonal 
pools of SF3B1K700E MCF-10A cells with 
overexpressed GFP or PHGDH (upper 
left). Quantification of growth of over-
expression populations in media with or 
without SG (lower left) and represen-
tative images (right). Scale bars: 100 
μm. (B) PHGDH Western blot in GFP- or 
PHGDH-overexpressed populations of 
SF3B1K700E hTERT-IMEC cells (upper), and 
quantification of their growth in media 
with or without SG (lower). (C) Western 
blot of PHGDH in SF3B1H662Q Nalm6 cells 
after overexpression of vector or PHGDH 
(upper), and +SG and –SG growth quan-
tification (lower). (D) Rescue of  
–SG growth by increasing concentra-
tions of phosphohydroxypyruvate (PHP) 
in SF3B1MUT cells. All data are represen-
tative of 2 independent experiments 
and 3 biologic replicates per condition 
were used. **P < 0.01, ***P < 0.001, 
****P < 0.0001 for Dunnett’s test com-
paring all GFP/vector-overexpressed 
to all PHGDH-overexpressed cells, but 
independent polyclonal populations are 
also shown.
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and enriched in SF3B1MUT cells, in the form of cryptic SLC3A2. We 
suspect this was detectable because SLC3A2 is a highly abundant 
protein, but this finding does suggest that other, less abundant 
cryptic proteins may also be present in SF3B1MUT cells. Whether 
—or how—these various protein alterations contribute to the onco-
genicity of SF3B1 mutations is unknown. Tumor suppressor hap-
loinsufficiency has been suggested as one possible mechanism 
(9), and there were tumor suppressor proteins downregulated by 
SF3B1MUT in our study, such as NF1 and FANCD2 (Supplemental 
Table 7). An additional possibility is that cryptic proteins enriched 
in SF3B1MUT cells could serve a gain-of-function oncogenic role, as 
has been suggested for the Notch pathway gene DVL2 in CLL (45). 
At the same time, such cryptic proteins might have implications 
for immune recognition of SF3B1MUT cancers. While most cryptic 
transcripts induced by mutant SF3B1 are also detectable—albeit 
at much lower levels—in SF3B1WT cells, some could be sufficient-
ly specific to SF3B1MUT cells so as to produce cryptic peptides that 
would be recognized as nonself by the host immune system. If so, 
immunotherapeutic strategies aimed at targeting these putative 
missplicing-associated neo-antigens may afford therapeutic ben-
efit, a testable hypothesis that we are currently investigating.
Our findings also demonstrate that SF3B1 mutations cause a 
specific deregulation of metabolic genes and reprogramming of 
cell metabolism, characterized by decreases in mitochondrial com-
plex III formation, mitochondrial respiration, and flux through the 
serine synthesis pathway. In breast cancer, SF3B1 mutations rare-
ly occur in triple-negative cases, and it is notable that this recep-
tor subtype is highly dependent on the serine synthesis pathway, 
in some cases exhibiting amplification of PHGDH (36, 37). While 
inverse association does not necessarily equal mutual exclusiv-
ity, it could be that one reason acquisition of SF3B1 mutations is 
disfavored in triple-negative breast tumors is due to their serine 
synthesis pathway–suppressing effects. It is also worth noting that 
a defining feature of MDS driven by SF3B1MUT is the ring sidero-
blast, which represents a pathologic deposit of iron in the matrix 
of structurally abnormal mitochondria that is accompanied by 
aberrant heme metabolism (4, 46). As suppression of PHGDH has 
heightened sensitivity to SG starvation in SF3B1MUT cells might be 
exploited therapeutically in vivo. Vousden and colleagues have 
shown that mice fed an SG-free diet will achieve a 60% reduc-
tion in blood SG levels, can tolerate the dietary modification, 
and in certain contexts will exhibit slower tumor growth (43, 44). 
We therefore performed xenograft experiments with SF3B1K700E 
HNT34 cells in mice fed SG-free or amino acid–replete diets. We 
first employed HNT34 cells both because of their native SF3B1 
mutation and because additional in vitro experiments showed 
their growth could be suppressed by partial serine depletion, a 
state which reflects the effects of dietary restriction in vivo (Sup-
plemental Figure 12). As shown in Figure 7A, HNT34-derived 
tumors in mice fed an SG-free diet grew more slowly than those 
of animals that received a control, SG-containing diet. To deter-
mine whether this in vivo inhibitory effect could be seen in other 
SF3B1MUT cells, we also tested the growth of SF3B1K666N MUTZ3 
cells. As shown in Figure 7B, the growth of MUTZ3-derived tumors 
was also decreased in mice fed SG-free food. These data thus pro-
vide evidence that SF3B1-mutant cells can be therapeutically tar-
geted in vivo by dietary restriction of serine and glycine.
Discussion
Here we report that hotspot mutations in the spliceosome pro-
tein SF3B1 cause a reshaping of the proteome, reprogramming of 
cellular metabolism, and vulnerability to deprivation of the non-
essential amino acid serine. These findings have several novel 
implications. While previous work has elegantly demonstrated 
the mechanism by which mutant SF3B1 induces aberrant splic-
ing, understanding of its consequences on the proteome and 
downstream cellular processes is limited (9, 10). We found that 
the SF3B1MUT proteome has a dominant pattern of protein down-
regulation in genes affected by aberrant splicing. For many, the 
likely mechanism is NMD-induced mRNA downregulation. For 
others, it is likely translational or posttranslational, which might 
occur, for example, through impaired stability of proteins har-
boring indels created by cryptic splicing. We also found evidence 
that protein with a novel in-frame peptide insertion was expressed 
Figure 7. Cancer cells with naturally acquired SF3B1 mutation show vulnerability to serine and glycine starvation in vivo. (A) HNT34 cells were subcuta-
neously injected into NSG mice given +SG or –SG diets, and tumor volume measurements were obtained starting at 5 weeks, with 10 biologic replicates in 
each group. (B) MUTZ3 cells were subcutaneously injected into NSGS mice given +SG or –SG diets and tumors were excised from euthanized animals and 
measured at week 4, with 4 biologic replicates in each group. ***P < 0.001, **P < 0.01, *P < 0.05 for t tests between dietary groups.
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to normal cells, as serine starvation appears well tolerated in mice 
(31, 43). This favorable toxicity profile may, in turn, allow dietary 
serine restriction to be combined with other treatments, as has 
been done in mice with biguanides and glutaminase inhibitors 
(24, 44, 50). It is also conceivable that in vivo administration of a 
serine-depleting enzyme could produce even greater serine depri-
vation and anticancer activity while still remaining tolerable to the 
host. Indeed, asparaginase is a backbone of curative therapy for 
acute lymphoblastic leukemia, and arginine-depleting enzymes 
have shown signs of anticancer activity in patients (51). Wheth-
er serine deprivation will be tolerable or effective in humans is 
unknown, but our findings provide a rationale for investigating 
this therapeutic strategy in patients with SF3B1-mutant cancers.
Methods
Cell lines. HEK293T cells were from ATCC and grown in DMEM/10% 
FBS. MCF-10A cells were from ATCC and grown in DMEM/F12 with 
5% horse serum, 20 ng/mL EGF, 10 μg/mL insulin, 0.5 μg/mL hydro-
cortisone, and 0.1 μg/mL cholera toxin. Gene-targeted MCF-10A 
derivatives were grown in the same media, except PIK3CAE545K knock-
ins (used as a control for the experiment shown in Supplemental Figure 
7), which were cultured without EGF. hTERT-IMEC cells were a gift 
from JW Shay (UT Southwestern Medical Center, Dallas, TX) and were 
cultured in MCF-10A media, except horse serum was substituted with 
2% charcoal dextran stripped FBS (52). HNT34, MUTZ, and CMLT1 
cells were from DSMZ. Nalm6 WT and SF3B1+/H662Q cells were from 
Horizon discovery, as were T47D WT, SF3B1+/K700E, and SF3B1+/K700K 
clones. K562, MOLM13, MONOMAC6, MV411, TF1, and KASUMI1 
cells were gifts from LP Gondek (Johns Hopkins University, Baltimore, 
MD). KG1 cells were a gift from RA Casero (Johns Hopkins Universi-
ty, Baltimore, MD). All leukemia cells were grown in RPMI/20% FBS, 
with supplements as follows: 10 ng/mL GM-CSF for MUTZ3, 2 ng/mL 
GM-CSF for TF1, and 10 μg/mL insulin for MONOMAC6. T47D cells 
were grown in RPMI/10% FBS. SF3B1 genotype was confirmed in all 
lines by Sanger sequencing of exons 13–24. STR cell line authentication 
and mycoplasma testing was done upon receipt and routinely thereaf-
ter, with last testing done April 2018.
Gene targeting. Gene targeting was carried out using recombinant 
AAV technology as previously described (53). Briefly, AAV targeting 
vectors were produced by ligating PCR-generated homology arms 
spanning intron 12 to intron 17 of the SF3B1 gene into a pSEPT-con-
taining AAV plasmid backbone (Agilent), which confers geneticin 
resistance through a promoterless IRES-NEO cassette. Site-directed 
mutagenesis was then performed to generate the K700E and R702R 
alterations (Supplemental Figure 1). Virus was prepared by trans-
fecting HEK-293T cells with pHelper, pRC (Agilent) and respective 
SF3B1 AAV plasmids. Breast epithelial cells were infected, and sin-
gle geneticin-resistant clones were isolated and assayed for integra-
tion of the targeting cassette with PCR. Successfully targeted clones 
were exposed to Cre-expressing adenovirus to remove the neomy-
cin cassette. All knockins underwent Sanger sequencing of genomic 
DNA and cDNA to ensure presence and transcription of the intended 
mutation. Primer sequences used for homology arm amplification are 
shown in Supplemental Table 10.
Transcriptome analysis. Total RNA was harvested from cultured 
cells using RNeasy and Qiashredder kits (Qiagen). RNA-seq libraries 
were constructed using the Illumina TruSeq RNA Sample Preparation 
recently been shown to directly disturb mitochondrial homeostasis 
and heme synthesis in endothelial cells, it is possible that PHGDH 
missplicing and downregulation could contribute to mitochondrial 
dysfunction and altered heme metabolism in SF3B1MUT MDS (32). 
Moreover, impairment of the electron transport chain can itself 
produce ring sideroblasts, as exemplified by the sideroblastic ane-
mia caused by germline mutations in the ETC gene NDUFB11 (47). 
This raises the possibility that missplicing and downregulation of 
the ETC gene UQCC1 by SF3B1MUT could contribute to ring sidero-
blast formation in MDS. We believe future studies are warranted to 
investigate how the specific disease phenotypes of SF3B1MUT can-
cers are influenced by aberrant splicing of metabolic genes.
It is also tempting to speculate that, in addition to shaping the 
metabolic behavior of SF3B1MUT cells, reprogramming of energy 
metabolism could provide an advantage in the initiation and pro-
gression of SF3B1MUT cancers. Indeed, metabolic reprogramming 
is a veritable hallmark of cancer that can drive tumorigenesis 
through rewiring of nutrient utilization and changes in metabo-
lite-driven gene regulation (48). However, we believe it remains 
fundamentally mysterious how SF3B1 mutations confer a clonal 
advantage to cells, and that mystery was highlighted by our obser-
vations that knocking mutant SF3B1 into untransformed breast 
epithelial cells slowed rather than transformed their growth (Sup-
plemental Figure 7). Whatever they are, the advantages of SF3B1 
mutations are likely to be contingent upon the genetic coconspir-
ators and epigenetic differentiation of the cell, and it will be inter-
esting to explore, in additional models, what environmental and 
cell-intrinsic conditions unleash the oncogenic properties of SF3B1 
mutations, and whether metabolic reprogramming is involved.
Whether cause or consequence of cancer, the altered met-
abolic properties we observed in SF3B1MUT cells offered a novel 
vulnerability to deprivation of the nonessential amino acid serine. 
Previous studies have shown anticancer activity for serine restric-
tion, but less is known about the molecular determinants of cancer 
responsiveness to this treatment (24, 31, 43, 44, 49). Maddocks et 
al. showed that p53 mutation sensitizes HCT116 colon cancer cells 
to serine deprivation by favoring the diversion of residual serine 
into nucleotide rather than glutathione synthesis, but this group 
also found that a murine p53-mutant pancreas cancer model was 
resistant to serine deprivation, demonstrating the context-depen-
dence of p53 mutation on this phenotype (43, 44). We observed 
heightened sensitivity to serine starvation associated with SF3B1 
mutation in multiple contexts, including 2 independent breast 
epithelial cell knockin models, a breast cancer knockin model, a 
leukemia knockin model, and naturally mutated leukemia cells. 
We also found evidence that the mechanism underlying this vul-
nerability involves missplicing and downregulation of the serine 
synthesis pathway enzyme PHGDH, as restored expression of this 
enzyme was able to rescue growth without SG in SF3B1K700E breast 
epithelial cell knockins and SF3B1MUT leukemia cell knockins. Giv-
en the diversity of genes affected by SF3B1MUT missplicing, it would 
not be surprising if altered activity of other metabolic proteins in 
addition to PHGDH contributes to this phenotype. Nonetheless, 
we describe here a novel form of synthetic lethality for SF3B1MUT 
cells, in which a predictable missplicing event is tolerated by itself 
but not in the context of additional metabolic stress. The proposed 
therapy also has a target—exogenous serine—that is nonessential 
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ratio followed by overnight trypsin digestion at 37°C. Peptides were pre-
fractionated by basic RPLC chromatography using Waters X-bridge C18 
column, and 12 fractions were collected. Each fraction was subjected to 
LC-MS/MS analysis on a Thermo Orbitrap Fusion Lumos mass spec-
trometer. Peptides were separated on an EASY-Spray analytical column 
(2 μm, 50 cm, Thermo Scientific) over a 180-minute gradient. The data 
were acquired in a data-dependent manner in top speed mode over 3 
seconds. Peptides were fragmented in higher-energy collisional disso-
ciation (HCD) mode at 35% collision energy. Dynamic exclusion of 30 
seconds was included in the method. Data were analyzed in 2 ways. First, 
for routing, protein quantitation spectral data were searched against 
Human RefSeq data set (release 73) using SILAC-based quantitation 
method. Second, for identification of novel splice junction peptides, 
the spectral data were searched against a 3 frame translated transcrip-
tomic data obtained as a part of the same study. Peptide identification 
and quantification was done using Proteome Discoverer suite (version 
2.1, Thermo Fisher Scientific). Peptide spectral matches qualifying 1% 
FDR by decoy database search method were accepted. Western blotting 
was performed as previously described (56). The following antibodies 
were used: anti-UQCC1 (Sigma-Aldrich, HPA034875), anti-UQCC2 
(Sigma-Aldrich, HPA039111), anti-UQCRFS1 (Abcam, ab14746), anti-
UQCRC1 (Abcam, ab110252), anti-UQCRQ (Abcam, ab110255), anti-
MUT (Abcam, ab133672), anti-DLST (Abcam, ab187699), anti-PHGDH 
(Sigma-Aldrich, HPA021241), anti-β-Actin (Cell Signaling, 4970S), 
anti-GAPDH (Cell Signaling, 5174).
Gene ontology analysis. Proteins identified as downregulated or 
upregulated at log2 abundance ratios of ±0.5 in SF3B1K700E MCF-10A cells 
by SILAC were submitted to GO biological process enrichment analysis 
through the Gene Ontology Consortium (http://geneontology.org) (57). 
Overexpression experiments. For UQCC1 overexpression, canonical 
UQCC1 was PCR amplified from cDNA made from MCF-10A cells and 
cloned into the lentiviral vector pLX301 (Addgene plasmid 25895). The 
pEXP7-TET cassette from the BP Clonase Enzyme Kit (Thermo Fisher 
Scientific) was cloned into pLX301 as a vector control. Lentivirus was 
produced by transfection of 293T cells with pMD2.6 (Addgene plasmid 
12259), psPAX2 (Addgene plasmid 12260), and the pLX301 derivatives. 
For PHGDH overexpression in MCF-10A and hTERT-IMEC cells, we 
made lentivirus as above, but with pLJM5-WT PHGDH lentiviral vec-
tor (Addgene plasmid 83901). For GFP control virus, we replaced the 
PHGDH ORF in pLJM5-WT PHGDH with GFP from pmaxGFP (Lonza) 
and produced lentivirus otherwise as above. Breast epithelial cells were 
then infected with lentivirus, selected with puromycin (UQCC1) or 
hygromycin (PHGDH), and collected as independent polyclonal pools 
of stably expressing cells. For PHGDH overexpression in Nalm6 cells, 
the full-length PHGDH open reading frame was PCR amplified from 
cDNA from MCF-10A cells, inserted into the lentiviral vector pLX301, 
and lentivirus produced as above. The pEXP7-TET-pLX301 virus was 
used as a vector control, as above. Independent polyclonal Nalm6 pools 
of transduced cells were selected with puromycin.
Metabolite quantification. For MCF-10As, gene targeting control 
cells (R702R1) were grown over 4 days with or without 5 mM met-
formin, and SF3B1K700E knockin cells were also grown for 4 days, but 
seeded at a higher starting density so that cell confluency was similar 
by the end of the experiment. Media was changed at 48 and 72 hours. 
At the time of harvest, cell counting was done on extra replicates of 
cells cultured in the same conditions and used just for the purpose of 
determining the volume of trypsinized cells needed to pellet 5 × 106 
Kit v3. Sequencing was performed on an Illumina HiScanSQ system 
to obtain a total of more than 40 million paired-end reads of 101 bp 
in length per replicate. Reads were aligned using TopHat (version 
2.0.10) against the GRCh38/hg38 version of the human genome, and 
assembly was carried out with Cufflinks pipeline. Differential mRNA 
expression between mutant and control cells was analyzed with 
DESeq2 from read counts obtained using HTSeq (htseq-count) and 
GENCODE (release 26) gene annotations. Four mutant MCF10A rep-
licates (2 from the K700E1 clone and 2 from K700E2) and 4 WT repli-
cates (2 from R702R1 and 2 from TWT1) were compared. Splice junc-
tions were identified by RSeQC (version 2.6.4) and quantified using 
DEXseq, and PSI values for junctions were determined by dividing the 
read counts for a given junction by all read counts that included either 
the donor or acceptor site. Junctions with coverage of at least 10 reads 
in mutant samples were included, and a PSI threshold of 5 or more 
was employed. Novel junctions were those not found in major tran-
scriptome databases, including KnownGene, AceView, and Ensembl. 
Splicing events were classified using exon-intron annotations from 
the GRCh38/hg38 reference assembly. Because it was shown to com-
prise a very minor fraction of SF3B1MUT-associated missplicing events 
(9), intron retention was not included in the analysis. A junction was 
classified as NMD-sensitive if it produced a premature termination 
codon (PTC) more than 55 nucleotides upstream of the last exon-exon 
boundary (54). Transcriptome data, including raw fastq files, identi-
fied junctions, and assembled transcript annotations, were depos-
ited in NCBI’s Gene Expression Omnibus (GEO) and are accessible 
through GEO Series accession number GSE134475 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE134475). For splice junction 
usage between TCGA breast tumors and isogenic MCF-10A cells, all 
splicing events identified as upregulated in SF3B1MUT breast tumors 
by Darman et al. were included except intron retention. For whole-
gene mRNA expression comparison between isogenic MCF-10As and 
TCGA/METABRIC data sets, the latter was obtained through cBio-
portal and those genes with altered expression in SF3B1MUT vs SF3B1WT 
tumors at a false discovery q value of less than 0.05 were included. The 
criteria for including SF3B1 mutations from the TCGA, METABRIC, 
and Beat AML data sets in the SF3B1MUT group were that the mutations 
are recurrent in primary human cancers, create in-frame amino acid 
changes, and are located in the HEAT repeats domain, as DeBoever 
et al. previously showed that mutations outside the HEAT repeats do 
not exhibit the same cryptic splicing pattern (55). Validation of aber-
rant junctions was done with endpoint PCR on cDNA from cells using 
primers designed to amplify both the cryptic junction of interest and 
its paired canonical junction. These primers sequences are provided in 
Supplemental Table 10.
Proteome analysis. SILAC-based mass spectrometry of MCF-10A 
cells was performed as previously described (19). Briefly, 2 indepen-
dent K700E clones and a TWT clone were propagated for more than 
7 population doublings in DMEM/F12 SILAC media deficient in both 
l-lysine and l-arginine (Thermo Fisher Scientific) and supplemented 
with light lysine (K) and arginine (R) for light, 2H4-K and 13C6-R for 
medium state, and 13C165N2-K and 13C165N4-R for heavy state label-
ing (Cambridge Isotope Laboratories). Cells were lysed in 9M urea in 
ammonium bicarbonate buffer and equal amounts of proteome from 
the 3 SILAC-labeled states were mixed. Proteome was subjected to 
reduction and alkylation with 10 mM DTT and 20 mM iodoacetamide, 
respectively. Sequencing grade trypsin (Promega) was added in a 1:20 
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to wells, and the plate was incubated at 37°C without CO2 for 1 hour. 
The plate was then loaded into the Seahorse machine and readings of 
oxygen and pH levels were taken before and after injections of 3 μM 
oligomycin, 4 μM FCCP, 2 μM antimycin, and 2 μM rotenone. Oxygen 
consumption rate and extracellular acidification rate were analyzed 
using Wave 2.4 software.
Serine and glycine starvation. Amino acid–free RPMI powder (US 
Biological, R9010-01) was individually reconstituted with RPMI-stan-
dard concentrations of amino acids (Sigma-Aldrich) as needed for 
experimental conditions. All serum used for starvation experiments 
was dialyzed FBS (dFBS, Thermo Fisher Scientific, 26400044). For 
MCF-10A and hTERT-IMEC cells, which were found capable of grow-
ing in RPMI, supplements for breast epithelial cell growth (EGF, insu-
lin, cholera toxin, hydrocortisone) were added to reconstituted RPMI, 
with the same concentrations used for DMEM/F12 as detailed above, 
except 5% horse serum was substituted with 5% dFBS. MCF-10A 
isogenic cells were grown in +SG or –SG media for 9 days with media 
changes every 2 days, and viable cells were then counted with a Vi-Cell 
XR cell counter. Isogenic hTERT-IMEC cells were grown in +SG and 
–SG media for 6 days, at which point viable cells were counted. MCF-
10A and hTERT-IMEC cells overexpressing either GFP or PHGDH 
were cultured in +SG or –SG in the same manner, as were phosphohy-
droxypyruvate (PHP) rescue experiments, but with increasing concen-
trations (0–1 mM) of PHP. For Nalm6 isogenic cells, RPMI + 20% dFBS 
with or without SG was used, cells were seeded at a starting density of 
106 cells/mL, equal volumes of additional +SG or –SG media were add-
ed at 48 hours and 96 hours, and cell mass/viability was determined 
on day 6 with alamarBlue, per the manufacturer’s protocol. Other leu-
kemia cell lines were cultured in +SG or –SG media using RPMI + 20% 
dialyzed FBS and, where required, the same supplements (GM-CSF, 
insulin) as in their routine culture media. Cells were seeded at a start-
ing density of 106 cells/mL, an equal volume of additional +SG or –SG 
media was added at 48 hours, and cell mass/viability was quantified 
by alamarBlue on day 4. For starvation of serine-vs.-glycine-vs.-both 
experiments, HNT34 and MUTZ3 cells were seeded in respective 
media at 106 cells/mL and viable cells counted at 48 hours. For gradient 
starvation of serine, HNT34 cells were seeded at 106 cells/mL in media 
containing increasing increments of serine, from 0 to the standard 
RPMI concentration of 285 μM, and viable cells were counted at 96 
hours. For isogenic T47Ds, cells were seeded into 96-well low attach-
ment plates (Corning) at a density of 5000 cells per well in 200 μL of 
RPMI/10% dFBS with or without SG. Plates were spun at 1000g in a 
bench top centrifuge to form 3D spheroids and media topped up to 300 
μL per well the next day. Spheroids were grown for 16 days and quanti-
fied by cell titre glo viability assays (Promega). To replenish media, 100 
μL was removed and replaced with fresh media.
Mouse xenograft studies. Nine-week-old female NOD-scid IL2Rgnull 
(NSG) and 5-week old male NOD-scid IL2Rgnull-3/GM/SF (NSGS) 
mice were obtained from The Jackson Laboratory. Mice were started 
on –SG or +SG pellets (Test Diet 5CC7) beginning 1 week before cell 
injections. For HNT34 cells, 107 cells were injected into the flanks of 
NSG mice on day 0. Mice were continued on +SG or –SG diets, and 
tumors in the +SG group first became measurable at week 5. Tumor 
measurements were made weekly for 4 weeks, after which the mice 
were euthanized. For MUTZ3 cells, 107 cells were injected into the 
flanks of NSGS mice on day 0, and mice were euthanized at week 4, at 
which point tumors were dissected from flanks and measured.
cells in the samples of interest, to minimize processing time. Cells 
were trypsinized for approximately 1 minute with 0.25% trypsin, and 
the predetermined volumes were spun and pellets snap-frozen in liq-
uid nitrogen. The protein content of samples was then quantified using 
the remaining trypsinized cells with Pierce 660 per the manufacturer’s 
protocol for use in normalization of final metabolite levels. The frozen 
pellets were shipped to Biocrates for extraction and quantification of 
energy metabolites by mass spectrometry. Orthogonal validation of 
aspartate levels was performed using similar culture conditions, but 
with independent isogenic MCF-10A clones using the Aspartate Assay 
Kit from Sigma-Aldrich (MAK095) per the manufacturer’s protocol.
For hTERT-IMECs, WT and SF3B1K700E knockin cells were grown 
in 10-cm dishes in +SG and –SG media for 42 hours, and media was 
refreshed, but with 13C-glucose for an additional 6 hours. Media was 
then withdrawn from the dishes and ice-cold 80% MeOH was added 
directly to cells. Cells were scraped off the dish and flash frozen in liq-
uid nitrogen. Samples were vortexed and stored at –80°C for at least 2 
hours to precipitate protein. Protein obtained from cells during metab-
olite extraction was quantified using BCA per the manufacturer’s pro-
tocol (MilliporeSigma) and protein levels were used for normalization 
of total ion abundance levels in the samples. Metabolite-containing 
supernatant was isolated after centrifugation at 15,000g for 10 min-
utes and dried under nitrogen gas and frozen at –80°C for subsequent 
analysis by liquid-chromatography mass spectrometry (LC-MS). 
Dried metabolite extracts were resuspended in 50% acetonitrile 
solution. LC-MS–based metabolomics profiling was performed on an 
Agilent LC-MS system consisting of an Agilent 1290 Infinity Binary 
UHPLC pump and a 6230 time-of-flight mass spectrometer. Chro-
matographic separations were performed using an Agilent 1290 ultra 
high-performance liquid chromatography system with a wellplate 
autosampler. An ion pairing method was developed using a C18 col-
umn (Agilent Zorbax Extend C18, 2.1 × 150 mm, 1.8 μm) with tribu-
tylamine as an ion-pairing agent, which enables the detection of most 
of the metabolites in central carbon metabolism. The LC parameters 
were as follows: autosampler temperature, 4°C; injection volume, 2 μL; 
column temperature, 40°C; and flow rate, 0.25 mL/min. The solvents 
and optimized gradient conditions for LC were as follows: Solvent A, 
97% water/3% methanol containing 5 mM TBA and 5.5 mM acetic 
acid; Solvent B, methanol containing 5 mM TBA and 5.5 mM acetic 
acid; a nonlinear gradient from 0% B to 99% B in 22 minutes with 5 
minutes of post-run time. A 6520 accurate-mass Q-TOF LC-MS sys-
tem (Agilent) equipped with a dual electrospray (ESI) ion source was 
operated in negative-ion mode for metabolic profiling. The optimized 
ESI Q-TOF parameters for MS experiments were: ion polarity, nega-
tive; gas temperature, 325°C; drying gas, 10 L/min; nebulizer pressure, 
45 psig; capillary voltage, 4000 V; fragmentor, 140 V; skimmer, 65 V; 
mass range, 50–1100 m/z; acquisition rate, 1.5 spectra/s; instrument 
state, extended dynamic range (1700 m/z, 2 GHz). Spectra were inter-
nally mass calibrated in real time by continuous infusion of a refer-
ence mass solution using an isocratic pump connected to a dual spray-
er feeding into an electrospray ionization source. Data were acquired 
with MassHunter Acquisition software (Agilent Technologies).
For quantification of oxygen consumption rate, isogenic MCF-10A 
cells were seeded at 28,000 cells per well in Seahorse XF96 Analyzer 
plates in regular media and incubated at 37°C with 5% CO2 overnight. 
Media was then removed, cells were washed, Seahorse media (RPMI 
+ 17.5 mm glucose + 1 mM pyruvate + 2 mM glutamine) was added 
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less than 0.05 was used to test for significance between groups. All 
graphs show mean ± SEM.
Study approval. The animal care and use protocol of this study was 
approved by the IACUC of the Johns Hopkins University.
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Proliferation and 3D growth. Baseline proliferation in MCF-10A and 
hTERT-IMEC cells was determined in standard DMEM/F12-supple-
mented media. Media was changed every 2 days, and cells were tryp-
sinized and counted on day 6 (MCF-10A) or day 5 (hTERT-IMECs). For 
growth factor–independent proliferation, MCF-10A cells were seeded 
at low density in T25 flasks and grown in standard DMEM/F12-supple-
mented media, but without EGF for 3 weeks, at which point they were 
stained with crystal violet and photographed. For mammosphere for-
mation, isogenic MCF-10A cells were grown in standard media com-
bined with Matrigel for 10 days, at which point representative photo-
graphs were taken. Soft agar colony formation assays were performed 
as previously described (56).
Statistics. Significance of ΔPSI of splice junctions between 
mutant and control MCF-10A cells was tested using a moderated, 
2-tailed t test with P less than 0.01 and Benjamini-Hochberg cor-
rection q less than 0.05. Genes differentially regulated in SF3B1MUT 
breast tumors from TCGA and METABRIC were included at FDRs 
of less than 0.10 and less than 0.05, respectively, due to the larg-
er overall number of tumors in the METABRIC cohort. For gene 
ontology analysis, processes enriched at P less than 0.05 by Fish-
er’s exact test with q less than 0.05 by Benjamini-Hochberg FDR 
correction were first captured and then further filtered for those 
with a fold enrichment of greater than 3. For xenotransplantation, 
tumor volumes and statistical comparisons were calculated as pre-
viously described (58). For growth rescue with PHP, Dunnett’s test 
was applied to compare control cells with multiple increasing doses 
of PHP. For all other experiments, a 2-tailed Student’s t test with P 
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